Exebacase - ContraFect

Drug Profile

Exebacase - ContraFect

Alternative Names: CF-301

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rockefeller University
  • Developer ContraFect
  • Class Antibacterials; Endolysins; Enzymes
  • Mechanism of Action Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bacteraemia
  • No development reported Skin and soft tissue infections

Most Recent Events

  • 07 Jun 2018 Antimicrobial data from a preclinical trial in Bacteremia presented at ASM Microbe (ASMM - 2018)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study in Bacteraemia presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018) ,
  • 25 May 2017 Phase-II clinical trials in Bacteraemia (Adjunctive treatment) in North America, South America, Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top